RS66072B1 - Nova upotreba agonista angiotenzinskog ii receptora tipa 2 - Google Patents

Nova upotreba agonista angiotenzinskog ii receptora tipa 2

Info

Publication number
RS66072B1
RS66072B1 RS20241153A RSP20241153A RS66072B1 RS 66072 B1 RS66072 B1 RS 66072B1 RS 20241153 A RS20241153 A RS 20241153A RS P20241153 A RSP20241153 A RS P20241153A RS 66072 B1 RS66072 B1 RS 66072B1
Authority
RS
Serbia
Prior art keywords
respiratory
virus
use according
compound
treatment
Prior art date
Application number
RS20241153A
Other languages
English (en)
Serbian (sr)
Inventor
Carl-Johan Dalsgaard
Johan Raud
Rohit Batta
Original Assignee
Vicore Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2004209.9A external-priority patent/GB202004209D0/en
Priority claimed from GBGB2009574.1A external-priority patent/GB202009574D0/en
Application filed by Vicore Pharma Ab filed Critical Vicore Pharma Ab
Publication of RS66072B1 publication Critical patent/RS66072B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20241153A 2020-03-23 2021-03-22 Nova upotreba agonista angiotenzinskog ii receptora tipa 2 RS66072B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2004209.9A GB202004209D0 (en) 2020-03-23 2020-03-23 New use
GBGB2009574.1A GB202009574D0 (en) 2020-06-23 2020-06-23 New use
US17/113,416 US11123329B1 (en) 2020-03-23 2020-12-07 Use of angiotensin II type 2 receptor agonist
PCT/GB2021/050699 WO2021191592A1 (en) 2020-03-23 2021-03-22 New use of angiotensin ii type 2 receptor agonist
EP21715306.3A EP4125881B1 (en) 2020-03-23 2021-03-22 New use of angiotensin ii type 2 receptor agonist

Publications (1)

Publication Number Publication Date
RS66072B1 true RS66072B1 (sr) 2024-11-29

Family

ID=77747178

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20241153A RS66072B1 (sr) 2020-03-23 2021-03-22 Nova upotreba agonista angiotenzinskog ii receptora tipa 2

Country Status (12)

Country Link
US (2) US11123329B1 (cg-RX-API-DMAC7.html)
EP (1) EP4125881B1 (cg-RX-API-DMAC7.html)
JP (1) JP7671305B2 (cg-RX-API-DMAC7.html)
CN (1) CN115605201A (cg-RX-API-DMAC7.html)
CA (1) CA3176108A1 (cg-RX-API-DMAC7.html)
ES (1) ES2992423T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241435T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068662T2 (cg-RX-API-DMAC7.html)
PL (1) PL4125881T3 (cg-RX-API-DMAC7.html)
RS (1) RS66072B1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400427T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021191592A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202004094D0 (en) * 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
US20220233480A1 (en) * 2020-03-23 2022-07-28 Vicore Pharma Ab Use of angiotensin ii type 2 receptor agonist
JP7798791B2 (ja) * 2020-04-22 2026-01-14 エアウェイ・セラピューティクス・インコーポレイテッド ウイルス感染症の治療のための肺サーファクタントタンパク質dの使用
CN117209555B (zh) * 2021-09-30 2024-12-03 中国科学院上海药物研究所 一类氰基化合物、其制备方法及用途
CN115583984A (zh) * 2022-01-11 2023-01-10 嘉兴安谛康生物科技有限公司 氮杂螺类化合物及其制备方法、药物组合物和用途
CN114948950A (zh) * 2022-01-19 2022-08-30 广州谷森制药有限公司 一种药物组合物及其抗病毒用途
TW202432112A (zh) * 2023-01-16 2024-08-16 大陸商海南先聲藥業有限公司 抗病毒藥物組合物及其製備方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60222409T2 (de) 2001-05-31 2008-09-25 Vicore Pharma Ab Trizyklische verbindungen, nützlich als angiotensin ii agonisten
EP1723962A1 (en) 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
HK1244232A1 (zh) 2015-03-02 2018-08-03 维科尔药物公司 用於治疗肺纤维化的血管紧张素ii受体激动剂
GB201818164D0 (en) 2018-11-07 2018-12-19 Vicore Pharma Ab New composition

Also Published As

Publication number Publication date
HUE068662T2 (hu) 2025-01-28
JP7671305B2 (ja) 2025-05-01
HRP20241435T1 (hr) 2024-12-20
CN115605201A (zh) 2023-01-13
WO2021191592A1 (en) 2021-09-30
ES2992423T3 (es) 2024-12-12
PL4125881T3 (pl) 2024-12-02
SMT202400427T1 (it) 2024-11-15
US11123329B1 (en) 2021-09-21
EP4125881B1 (en) 2024-07-24
CA3176108A1 (en) 2021-09-30
EP4125881A1 (en) 2023-02-08
US20210386712A1 (en) 2021-12-16
JP2023520323A (ja) 2023-05-17
EP4125881C0 (en) 2024-07-24
US20210290596A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
EP4125881B1 (en) New use of angiotensin ii type 2 receptor agonist
RU2766577C2 (ru) Способы лечения эозинофильного эзофагита
US12551469B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
US20110293686A1 (en) Anti-viral compositions and methods for administration
US20230129866A1 (en) Methods of treating respiratory disease with deupirfenidone
Peng et al. A comprehensive summary of the knowledge on COVID-19 treatment
JP2013529627A (ja) ヒドロキシクロロキンまたはヒドロキシクロロキンおよび抗ウイルス剤の組合せを使用するc型肝炎ウイルス関連疾患の処置
WO2012104402A1 (en) Treatment of severe persitent asthma with masitinib
EP4313043A1 (en) Treatment of hidradenitis suppurativa with orismilast
Shuhui et al. Jinyinqingre Oral Liquid alleviates LPS-induced acute lung injury by inhibiting the NF-κB/NLRP3/GSDMD pathway
Macha et al. Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers
CN113260363A (zh) 格拉普兰特(grapiprant)单位剂型
KR20220150348A (ko) 코로나바이러스의 치료에 조합하여 사용하기 위한 pld
US20220233480A1 (en) Use of angiotensin ii type 2 receptor agonist
MX2009001248A (es) Tratamiento con glucocorticoide de liberacion prolongada de enfermedad reumatoide.
Huerta et al. Forskolin compared with beclomethasone for prevention of asthma attacks: a single-blind clinical trial
HK40081689A (en) New use of angiotensin ii type 2 receptor agonist
HK40081689B (en) New use of angiotensin ii type 2 receptor agonist
TW202144380A (zh) 用於治療冠狀病毒感染之化合物
US12115150B2 (en) Biomarkers of coronavirus pneumonia
WO2021204814A1 (en) Nachr, such as nicotine, for use in the prevention and the treatment of covid-19 disease
WO2025090967A1 (en) Pharmacological agonist of klf2 reduces osteoclast differentiation, inflammation, and covid
Galleani et al. Remdesivir-Induced Nonimmediate Cutaneous Hypersensitivity Reaction
WO2023222332A1 (en) Diphenyl ureas for the treatment of viral infections
TR202022556A2 (tr) Lökotrien ltd4 reseptör antagonisti montelukastın sars-cov-2 virüs dual inhibisyonu.